Methods, systems, and compositions for maintaining functioning drainage blebs associated with minimally invasive micro sclerostomy

Abstract

Methods, systems, and compositions for maintaining functioning drainage blebs to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The methods, systems, and compositions feature the combination of a minimally invasive micro sclerostomy (MIMS) procedure and the application of beta radiation to a target area. The beta radiation can function to inhibit or reduce the inflammation and / or fibrogenesis that typically occurs after a MIMS procedure and leads to hole and / or bleb failure. By reducing inflammation and / or fibrogenesis, the MIMS holes and / or blebs can remain functioning appropriately.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a non-provisional, and claims benefit of U.S. Patent Application No. 62 / 738,573 filed Sep. 28, 2018 the specification(s) of which is / are incorporated herein in their entirety by reference.FIELD OF THE INVENTION[0002]The present invention relates to methods, systems, and compositions for treating glaucoma treatment-associated drainage blebs and / or holes with beta radiation to maintain functioning blebs and / or holes. The present invention also relates to the use of a Minimally Invasive Micro Sclerostomy (MIMS) and beta radiation for treating glaucoma.BACKGROUND OF THE INVENTIONGlaucoma[0003]Glaucoma is the leading cause of irreversible blindness and represents a family of diseases with a characteristic optic neuropathy. Therapy for this group of diseases is principally focused at reducing the intraocular pressure (IOP) of the fluid inside the eye (aqueous humor), thus averting ongoing damage to the optic nerve.[0004]Gla...

AI Technical Summary

Benefits of technology

[0096]Treat, Treatment, Treating: These terms refer to both therapeutic treatment, e.g., elimination of a disease, disorder, or condition, and prophylactic or preventative measures, e.g., preventing or slowing the development of a disease or condition, reducing at least one adverse effect or symptom of a disease, condition, or disorder, etc. Treatment may be “effective” if one or more symptoms or clinical markers are reduced as that term is defined herein. Alternatively, a treatment may be “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already diagnosed with a particular disease, disorder, or condition, as well as those likely to develop a particular disease, disorder, or condition due to genetic susceptibility or other factors.

Problems solved by technology

Further, there would be no motivation to administer beta radiation to the tissues surrounding the MIMS drainage channel and / or the portion of the bleb above the MIMS drainage channel because the ophthalmology community believes that the fibroblasts that cause scarring are not in the sclera at the MIMS drainage channel.

Images